Compass Pathways CEO: Psychedelics company will ‘go slow before we go fast’

Compass Pathways CEO Kabir Nath said the company will take a cautious approach to launching COMP360, its synthetic psilocybin therapy for treatment-resistant depression, saying bad early patient or provider experiences could harm the broader sector. Compass plans to complete a rolling FDA submission this quarter and aims to launch early next year, expecting a REMS and investing in provider training. In Phase 3 trials, roughly a quarter of patients responded after a single dose, rising to about 40% after a second dose three weeks later.